A study to analyze the drug prescribing pattern with their side effect profile and effect of such treatment on Quality of Life among patients of acne vulgaris disease.
Not Applicable
- Conditions
- Health Condition 1: L700- Acne vulgaris
- Registration Number
- CTRI/2024/05/066802
- Lead Sponsor
- Pramod Kumar
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Newly enrolled Acne vulgaris patients seeking medical intervention for first time at AIIMS Rishikesh
Age more than and equal to 15 years from either gender (male / female).
Patient willing to undergo treatment and follow ups.
Patient willing to give written informed consent to participate in study
Exclusion Criteria
Withdrawal of consent at any point after enrolment but before completion of follow-up.
Pregnant and Lactating women.
Patients diagnosed with systemic comorbidity/comorbidities requiring chronic treatment.
Any dermatologic disease other than acne vulgaris.
Patients with secondary causes of Acne like Drug induced Acne/acneiform eruptions.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1-To analyse drug prescribing pattern in acne vulgaris patients in relation to severity of acne and prevailing treatment guidelines. <br/ ><br>2-To assess effect of treatment on quality of life in acne vulgaris patients, using Dermatology Life Quality Index (DLQI) and acne- specific Cardiff Acne Disability Index (CADI) at multiple time points of therapy.Timepoint: 1-At baseline visit <br/ ><br>2-at 0(baseline), 3, and 6 months
- Secondary Outcome Measures
Name Time Method To assess effect of treatment on self-esteem in acne vulgaris patients, using Rosenberg Self-esteem Scale (RSES) at multiple time points of therapy.Timepoint: at 0(baseline), 3, and 6 months;To study the adverse event profile of treated acne vulgaris patients with active reporting of adverse events in patients treated with Retinoids.Timepoint: During OPD visits (3, and 6 months) and through telephonic calls.